Enovis Co. (NYSE:ENOV) Shares Sold by Entropy Technologies LP

Entropy Technologies LP decreased its position in Enovis Co. (NYSE:ENOV) by 28.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,707 shares of the company’s stock after selling 2,698 shares during the quarter. Entropy Technologies LP’s holdings in Enovis were worth $289,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of Enovis by 88.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock valued at $23,802,000 after purchasing an additional 179,276 shares during the period. Janus Henderson Group PLC increased its stake in shares of Enovis by 100.6% during the 1st quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock valued at $23,606,000 after acquiring an additional 189,584 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of Enovis by 13.3% during the 2nd quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company’s stock worth $12,864,000 after acquiring an additional 33,300 shares during the period. Sei Investments Co. boosted its position in shares of Enovis by 50.9% in the second quarter. Sei Investments Co. now owns 223,358 shares of the company’s stock worth $10,096,000 after acquiring an additional 75,317 shares during the last quarter. Finally, King Luther Capital Management Corp grew its holdings in Enovis by 45.2% in the second quarter. King Luther Capital Management Corp now owns 177,862 shares of the company’s stock valued at $8,039,000 after purchasing an additional 55,385 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ENOV. JPMorgan Chase & Co. decreased their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th. Evercore ISI reduced their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. Finally, JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Stock Up 1.8 %

Shares of NYSE:ENOV opened at $46.38 on Friday. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -21.18 and a beta of 1.91. The company has a 50 day moving average of $42.44 and a two-hundred day moving average of $45.20. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same period last year, the business earned $0.56 EPS. The business’s revenue was up 21.0% on a year-over-year basis. As a group, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.